e.g. proapoptotic drugs to the
mitochondria, antibiotics and
enzymes to the lysosomes, and
various anticancer drugs and
gene therapies to the nucleus.
The technologies described here
represent the tip of the iceberg
for the development of new drug
delivery systems. From both a
financial and a global health
care perspective, the promise
of administration methods that
allow localized treatment will
change the future of medicine.
1 Mejia Oneto J., Khan I., Seebald L.,
Royzen M. 2016. In Vivo Bioorthogonal
Chemistry Enables Local Hydrogel and
Systemic Pro-Drug To Treat Soft Tissue
Sarcoma. ACS Central Science 2016 2
( 7), 476-482.
About the Authors
Jose Mejia-Oneto is the Founder
and Chief Executive Officer
of Shasqi. He completed a
Ph.D. in organic chemistry at
Emory University and an MD
degree from the University
of Minnesota, followed by
residency studies in orthopedic
surgery at UC Davis, before
starting Shasqi in 2015.
Nathan A. Yee is a Senior
Chemist at Shasqi. He completed
a Ph.D. in chemistry at UC
Berkeley in 2017, with a focus
on chemical biology.
Valeria Revilla is a Senior
Scientist at Shasqi, specializing
in micro and molecular biology.
She holds an M.S. degree in
biotechnology from the Ensenada
Center for Scientific Research
and Higher Education, Mexico.
Jose Mejia-Oneto (Photo credit:
Sangeetha Srinivasan, Shasqi Inc.)
T. 973 575 7445 | INFO@MARCHESINIUSA.COM W WW. MARCHESINI.COM
THE BEST DESERVES THE BEST
Since 1992, Marchesini Group USA has been one
of the leading companies supplying the most technologically
advanced packaging solutions to the North American
pharmaceutical and cosmetic industries.
MARCHESINI GROUP USA: PROVIDING THE BEST SINCE 1992.